Agilent Technologies Inc. (NYSE:A) shares are up during Monday’s premarket session as the company announces the acquisition of Biocare Medical for around $950 million.
Synergies
Biocare Medical has been a prominent player in the pathology space, offering a range of immunohistochemistry and hybridization solutions.
Biocare has over 300 specialized antibodies and robust R&D capabilities.
It has consistently achieved double-digit revenue and profit growth since 2021, making it a valuable addition to Agilent’s offerings.
The addition of Biocare’s IHC antibodies, reagents, and instrument portfolio strengthens Agilent’s immunohistochemistry offering and broadens its reach across clinical and research pathology labs.
Agilent expects Biocare’s strong growth in the IHC market and its efficient product innovation capabilities to enhance it’s ability to develop and commercialize new IVD antibodies.
The deal is expected to be completed by Agilent’s fourth fiscal quarter of 2026, subject to customary closing conditions, including regulatory approvals.
Once finalized, Biocare will be integrated into Agilent’s Life Sciences and Diagnostics Markets Group.
The transaction is expected to boost Agilent’s revenue growth, margins, and non-instrument revenue mix in its first year.
It is also projected to become accretive to EPS roughly 12 months after closing.
As of January 31, 2026, Agilent’s cash and cash equivalents stood at $1.76 billion.
Stock Performance Insights
Over the past 12 months, Agilent’s stock has seen a decline of 5.60%, reflecting some challenges despite its strong market positioning. The stock is currently trading at $116.41, which is below its 20-day SMA of $123.62 and significantly below the 50-day SMA of $132.93. This positioning suggests a bearish short-term trend but needs to be viewed in the context of recent strategic moves like the Biocare acquisition.
The technical indicators show an oversold RSI of 28.41, which could indicate a potential rebound, while the MACD remains bearish. These mixed signals suggest that investors should watch for potential shifts in momentum following the integration of Biocare’s operations.
Upcoming Earnings Report
Agilent Technologies is slated to provide its next financial update on May 27, 2026.
With the earnings date approaching in 79 days, investors are keen to see how recent acquisitions like Biocare Medical will impact the company’s financial health.
- EPS Estimate: $1.41 (Up from $1.31 YoY)
- Revenue Estimate: $1.80 billion (Up from $1.67 billion YoY)
- Valuation: P/E of 25.4x (Indicates premium valuation)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $158.50. Recent analyst moves include:
- Morgan Stanley: Overweight (Lowers Target to $160.00) (Mar. 3)
- UBS: Buy (Lowers Target to $165.00) (Feb. 26)
- TD Cowen: Buy (Lowers Target to $157.00) (Feb. 26)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Agilent Technologies, highlighting its strengths and weaknesses compared to the broader market:
- Value: Neutral (Score: 31.64) — Reflects a balanced valuation in the current market.
- Quality: Neutral (Score: 40.97) — Indicates a moderate quality score, suggesting solid fundamentals.
- Momentum: Weak (Score: 18.23) — The stock is underperforming the broader market in terms of momentum.
The Verdict: Agilent Technologies’ Benzinga Edge signal reveals a mixed scenario. While the Quality and Value scores suggest a stable foundation, the weak Momentum score indicates potential challenges ahead, possibly influenced by market conditions and recent strategic moves.
Top ETF Exposure
- First Trust Water ETF (NYSE:FIW): 4.04% Weight
- Invesco Zacks Mid-Cap ETF (NYSE:CZA): 2.09% Weight
- Global X Telemedicine & Digital Health ETF (NASDAQ:EDOC): 4.13% Weight
Significance: Because A carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
A Price Action: Agilent Technologies shares were up 1.16% at $116.41 during premarket trading on Monday, according to Benzinga Pro data.
Photo via Shutterstock
